Skip to main content

Simon Schwartz Navarro

Senior scientist and advisor with specific interest in Nanomedicine and Advanced Therapies applied to unmet clinical needs. I am also acting as strategy coordinator to facilitate programs and initiatives that foster innovation in new treatments and diagnostic tools.

Institutions of which they are part

Senior researcher
Drug Delivery and Targeting
Vall Hebron Institut de Recerca
Cap de Secció
Bioquímica
Cross-departmental services
Currently acting as Strategy director of biobanking and bioresources at Vall d'hebron Campus. President of the European Society of Nanomedicine and Executive Board member of the International Society of Nanomedicine. Former director general of the Blood and Tissue Banc of Catalonia. Former director of CIBBIM-Nanomedicine. Former scientific associate director of CIBER-BBN and coordinator of technology transfer. Former director assistance of translational research at VHIR. H-index of 40, with more that 115 high impact publications and 17 transferred patents. Co-founder of 3 biotech companies (i.e, Bsure Medical ltd). Science Advisor of the European Nanomedicine Characterization Laboratory (EU-NCL). Member of the editorial Board of Precision Nanomedicine, J. Nanotechnology and of J. of Nanotheranostics. Former editorial Board member of Eur. J. Nanomedicine and Nanomedicine-NBM.

Research lines

Study of the molecular and cellular bases that maintain cell proliferation and metastasis in cancer

123 In recent years, cancer stem cell (CSC) theory has been used to explain resistance to therapy, the occurrence of relapses, and metastatic progression (Gener et al., Nanomedicine 2016, Mateo et al. Mol Cancer 2014). In the DDT group, we have developed a specific model for the study of CSCs in cell lines (Gener et al., Nanomedicine, 2015), which we are applying to different cancers (breast, colon, prostate, and pancreas). This model has allowed us to identify biomarkers and specific targets of tumor stem cells as well as agents capable of reversing the stemness character of CSCs. All this information is used later to develop new therapeutic and diagnostic strategies (see next point). In addition, in the group we delve into the role of the exosomes as an intercellular communication system and in their role in the maintenance of metastatic niches and tumor dissemination, as well as in their contribution to the progression of the disease. Projects: Alox5

IP: Simon Schwartz Navarro

Development of nanotechnology systems for the treatment and diagnosis of cancer

123 The identification of biomarkers in cancer stem cells allows us to develop targeted nanosystems, either because we use targeting moieties (antibodies or peptide sequences on the surface of the nanoparticles) or because we act directly on essential molecules in the maintenance of the CSC population (Pesarrodona et al., Biofabrication 2016). Therapeutic systems consist of biodegradable polymers that covalently anchor the drug or incorporate it into micellar structures (Gener et al., Nanomedicine, 2015, Andrade et al., Nanomedicine, 2015, Rocas et al., J Mater Chem, 2015). The use of these systems increases the efficiency and reduces the toxicity of conventional treatments (Schwartz, Nanomedicine 2017). In parallel, we also work on the combined use of chemotherapeutic treatments with alternative treatments such as hyperthermia using magnetic nanoparticles (Nocanther project). In the DDT group, nanotechnological systems are not only used for therapy but also for imaging, initially with non-directional nanosystems that accumulate in tumor areas due to the defect of the tumor vasculature (Candiota et al., J Nanobiotechnology, 2014 ; Bomatí-Miguel et al., J Nanoparticle Res), but also by means of directionalised systems. Projects: Alox5, Targets4Cancer, DiamESTar, NoCanTher and FIS

IP: Simon Schwartz Navarro, Ibane Abasolo Olaortua

Nanomedicine to improve enzyme replacement therapy in the treatment of lysosomal diseases

123 Lysosomal diseases are a group of rare diseases in which the defect of a lysosomal protein results in the accumulation in the lysosomes of non-metabolised products that derive in diverse pathologies. The current treatment of lysosomal diseases consists of enzyme replacement therapy in which the defective / mutant enzyme is administered parenterally. This therapy is applied with relative success in the diseases of Gaucher, Fabry, Pompe and mucopolysaccharidosis I, II, IV and VI. However, since recombinant proteins are not able to cross the blood-brain barrier. The treatment is not applicable in diseases with neuronal affectation (Sanfilippo, Niemann-Pick, Tay-Sachs, etc.). In this scenario, the DDT group attempts to improve enzyme replacement therapy in Fabry disease. To this end, specific models have been developed and various drug delivery systems have been tested from polymer capsules (Nazarenus et al, Particle & Particle System Charact 2015), chitosans (Gianotti et al, ACS Appl Mater Interfaces, 2016), liposomes Cabrera et al. Adv Heahtc Mat 2016, Cabrera et al., Nano Letters, 2013) and alternative systems (pegylation, aggressives, etc.). Work is currently being done on optimizing these systems to increase their effectiveness, but also to make them cross the blood brain barrier (Smart4Fabry project). Projects: Terarmet, Lipocell, Smart4Fabry

IP: Simon Schwartz Navarro, Ibane Abasolo Olaortua

Projects

ACTUALIZACIÓN DE EQUIPAMIENTOS DE ALTA TECNOLOGIA PARA LA PLATAFORMA DE IMAGEN PRECLINICA. ADQUISICION DE UN EQUIPO DE ULTRASONIDOS DE INVESTIGACION PRECLINICA

IP: Inmaculada Fuentes Camps
Collaborators: ACTUALIZACIÓN DE EQUIPAMIENTOS DE ALTA TECNOLOGIA PARA LA PLATAFORMA DE IMAGEN PRECLINICA. ADQUISICION DE UN EQUIPO DE ULTRASON, Diego Arango Corro, Anna Meseguer Navarro, ACTUALIZACIÓN DE EQUIPAMIENTOS DE ALTA TECNOLOGIA PARA LA PLATAFORMA DE IMAGEN PRECLINICA. ADQUISICION DE UN EQUIPO DE ULTRASON, Antonio Rodríguez Sinovas, Francesc Bosch Albareda, Victor Franco Puntes, José Raul Herance Camacho, Jordi Giralt López de Sagred, Màrius Aguirre Canyadell, Xavier Serres Créixams, Simon Schwartz Navarro, ACTUALIZACIÓN DE EQUIPAMIENTOS DE ALTA TECNOLOGIA PARA LA PLATAFORMA DE IMAGEN PRECLINICA. ADQUISICION DE UN EQUIPO DE ULTRASON, Joaquim Mateo Valderrama, Mario Marotta Baleriola, Anna Rosell Novel, Joan Genescà Ferrer
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 108390
Reference: EQC2019-006322-P
Duration: 01/01/2019 - 31/12/2020

Ministerio de Ciencia

ACTUALIZACIÓN DE EQUIPAMIENTOS DE ALTA TECNOLOGIA PARA LA PLATAFORMA DE IMAGEN PRECLINICA. ADQUISICION DE UN EQUIPO DE IMAGEN OPTICA

IP: Inmaculada Fuentes Camps
Collaborators: ACTUALIZACIÓN DE EQUIPAMIENTOS DE ALTA TECNOLOGIA PARA LA PLATAFORMA DE IMAGEN PRECLINICA. ADQUISICION DE UN EQUIPO DE IMAGEN OP, Diego Arango Corro, Ibane Abasolo Olaortua, Santiago Ramon y Cajal Agüeras, Miquel Vila Bover, Anna Meseguer Navarro, ACTUALIZACIÓN DE EQUIPAMIENTOS DE ALTA TECNOLOGIA PARA LA PLATAFORMA DE IMAGEN PRECLINICA. ADQUISICION DE UN EQUIPO DE IMAGEN OP, Joan Gavaldà Santapau, Francesc Bosch Albareda, Miguel Segura Ginard, Maria Martell Pérez-Alcalde, Victor Franco Puntes, Mª Jesús Cruz Carmona, Simon Schwartz Navarro, ACTUALIZACIÓN DE EQUIPAMIENTOS DE ALTA TECNOLOGIA PARA LA PLATAFORMA DE IMAGEN PRECLINICA. ADQUISICION DE UN EQUIPO DE IMAGEN OP, Joaquim Mateo Valderrama, Juan Angel Recio Conde , Anna Rosell Novel, Josep Roma Castanyer
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 134516.7
Reference: EQC2019-006306-P
Duration: 01/01/2019 - 31/12/2020

Ministerio de Ciencia

ADQUISICIÓN DE UN MICROSCOPIO MULTIDIMENSIONAL WIDEFIELD EQUIPADO PARA REALIZAR EXPERIMENTOS IN VIVO, DESTINADO A LA PLATAFORMA DE MICROSCOPÍA DE LA UNIDAD DE ALTA TECNOLOGÍA (UAT)

IP: Inmaculada Fuentes Camps
Collaborators: Maria Vicario Perez, Soledad Gallego Melcón, Fco Javier Santos Vicente, Diego Arango Corro, Gema Ariceta Iraola, Santiago Ramon y Cajal Agüeras, Marta Martínez Vicente, Anna Meseguer Navarro, Manuel Comabella Lopez, Ricardo Pujol Borrell, Joan Sahuquillo Barris, Joan Xavier Comella Carnicé, Miguel Segura Ginard, Simon Schwartz Navarro, Anna Rosell Novel, Meritxell Genesca Ferrer
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 177204.2
Reference: EQC2019-006309-P
Duration: 01/01/2019 - 31/12/2020

Ministerio de Ciencia

NanoDIRE-CT - Uso de nanobodies para terapia dirigida contra células madre tumorales

IP: Ibane Abasolo Olaortua
Collaborators: Simon Schwartz Navarro
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 322172.61
Reference: RTC2019-006809-1
Duration: 01/09/2020 - 31/08/2023

Ministerio de Ciencia

Related news

On World Cancer Research Day, we highlight the impact of VHIR projects in the field of oncology.

Onze investigadors i investigadores de Vall d’Hebron faran xerrades i tallers amb l’objectiu d’apropar la ciència a tothom.

Durant el mes de juny, organitzem tres activitats sobre assaigs clínics, genètica i imatges científiques.

Related professionals

Begoña Fernández Díez

Begoña Fernández Díez

Research technician
Drug Delivery and Targeting
Read more
Francesc Martínez Trucharte

Francesc Martínez Trucharte

Research technician
Drug Delivery and Targeting
Read more
Ignacio López Álvarez

Ignacio López Álvarez

Research technician
Drug Delivery and Targeting
Read more
Zamira Vanessa Diaz Riascos

Zamira Vanessa Diaz Riascos

Postdoctoral researcher
Drug Delivery and Targeting
Read more

Subscriu-te als nostres butlletíns i forma part de la vida del Campus

El Vall d’Hebron Barcelona Hospital Campus és un parc sanitari de referència mundial on assistència, recerca, docència i innovació es donen la mà.